Skip to content
POM-V Prescription Required Companion Animal

Versican Plus BbPi IN Nasal Drops, Lyophilisate and Solvent for Suspension for Dogs

Active ingredients: Bordetella bronchiseptica, Canine parainfluenza virus

Form

Drops

Species

Dogs

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5139

What it's used for

Active immunisation of dogs from 3 weeks of age: Bordetella bronchiseptica and  parainfluenza virus. Onset of immunity: 3 days after primary vaccination...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bordetella bronchiseptica +...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Versican Plus BbPi IN Nasal Drops, Lyophilisate and Solvent for Suspension for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Active immunisation of dogs from 3 weeks of age:
Bordetella
bronchiseptica and

parainfluenza virus.
Onset of immunity: 3 days after primary vaccination for Bordetella bronchiseptica.
7 days after primary vaccination for canine parainfluenza virus.
Duration of immunity: 1 year.

Revised: September 2024
AN: 01586/2023
None.
Dogs:
Very common
(>1 animal / 10 animals treated):
Nasal discharge
Common
(1 to 10 animals / 100 animals
treated):
Ocular discharge
Cough
Depression
Uncommon
(1 to 10 animals / 1,000 animals
treated):
Sneezing
1
Mild and generally subside without treatment within 1 to 3 days.
Mild to moderate and observed in vaccinated dogs within 48 hours to one week after
vaccination.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See also section 16 of the package leaflet for contact
details.
Vaccinate healthy animals only.
This veterinary medicinal product contains a live attenuated bacterial strain and
antibiotics may interfere with the veterinary medicinal product’s efficacy. Therefore,
vaccinated dogs should not receive antibiotic treatment. If antibiotics are used within
one week after vaccination, vaccination against Bordetella bronchiseptica should be
repeated e.g. with a Bb monovalent vaccine (if available) after completion of the
antibiotic treatment.

Special precautions for use in animals
After vaccination dogs may excrete the vaccine strain Bordetella bronchiseptica
up to 11 weeks and the vaccine strain canine parainfluenza virus for 8 days.
Unvaccinated dogs can manifest mild clinical signs such as sneezing and nasal and
ocular discharge after contact with vaccinated dogs.
The transmission of vaccine strains to cats, pigs and rodents could not be
demonstrated. However, as the possibility of transmission to non-target species
cannot be rejected, it is recommended to keep non-vaccinated animals out of close
contact with vaccinated dogs for at least 4 weeks.
Safe handling and proper administration of the veterinary medicinal product and
disposal of used material contribute to eliminating the risk of spreading the vaccine
antigens in the veterinary workplace.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Hands and tools should be disinfected after use.
In case of accidental self-administration during dilution of the veterinary medicinal
product or inhalation of the veterinary medicinal product in the form of aerosol during
administration into the nostril of a dog, seek medical advice immediately and show
the package leaflet or the label to the physician.
Although the risk that immunocompromised people are infected with Bordetella
bronchiseptica is extremely low, it should be borne in mind that dogs can excrete the
bacteria for up to several weeks after vaccination. Immunocompromised persons are
advised to avoid contact with the veterinary medicinal product and vaccinated dogs
during excretion.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.

Revised: September 2024
AN: 01586/2023
This veterinary medicinal product has been shown safe in dogs from 8 weeks of age
when given at the same time as vaccines of the Versican Plus/Biocan Novel and
Vanguard ranges containing live canine parvovirus, adenovirus, distemper virus,
parainfluenza virus as well as inactivated Leptospira and rabies virus. Mild (< 1 ºC),
transient increases in temperature were very commonly observed following co-
administration of these vaccines.
Efficacy after concurrent use has not been tested. Therefore, while safety of
concurrent use has been demonstrated, the veterinarian should take this into account
when deciding to administer the veterinary medicinal products at the same time.
Although proven safe it should not be necessary to give a parainfluenza vaccine
twice by two different routes, therefore the veterinarian should consider vaccination
options based on local availability of core vaccines without parainfluenza and
monovalent Bordetella vaccines.
No information is available on the safety and efficacy of this veterinary medicinal
product when used with any other veterinary medicinal product except the products
mentioned above. A decision to use this veterinary medicinal product before or after

Revised: September 2024
AN: 01586/2023
any other veterinary medicinal product therefore needs to be made on a case by
case basis.
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.
CCID50**
*CFU: Colony forming unit.
**CCID50: Cell culture infectious dose 50%.
Excipients:
For the full list of excipients, see section

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.